Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for SARS-CoV-2-induced pulmonary fibrosis
2020-002114-40Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis (PF) and Post-COVID-19 lung disease (PCLD) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual rate of decline in FVC. Started Jun 2020; status: active.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)Post-COVID-19 lung disease (PCLD)
Beyond the preview
Go deeper on 2020-002114-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002114-40.